The global inhalable drug market is anticipated to grow at a CAGR of 3.7% during the forecast period (2020-2026). The rising geriatric population that is more prone to respiratory diseases, augmentation in the predominance of respiratory and non-respiratory diseases, along with the rapidly changing lifestyles of the people creates demand for inhalable drugs and hence drives the growth of the market. The trend of smoking, drinking alcohol, and ill eating activity are increasing among the people which is a major risk for the development of various pulmonary diseases. As per the COPD Foundation of the US, the top three causes of COPD are environmental factors, smoking, and genetic factor. COPD is mostly occurred in people of age above 40 and having a history of smoking.
Get Free Sample link @ https://www.omrglobal.com/request-sample/inhalable-drugs-market
Non-respiratory diseases such as diabetes, Parkinson’s diseases, among many others are also becoming increasingly prevalent among the geriatric population. Owing to this, manufacturers are focused on the development of inhalable drugs for adult people as it is hard to swallow for them. For instance, in December 2018, the US FDA approved the INBRIJA drug, manufactured by Acorda Therapeutics as an inhalable prescription medicine for adults suffering from Parkinson’s disease. Thus, such aforementioned factors are likely to positively influence the growth of the market over the forecast period.
A full report of Global Inhalable Drugs Market available @ https://www.omrglobal.com/industry-reports/inhalable-drugs-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Inhalable Drugs Market by Applications
- Respiratory Diseases
- Non-Respiratory Diseases
Global Inhalable Drugs Market by Route of Administration
- Nasal
- Mouth
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- AptarGroup, Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Boehringer Ingelheim International GmbH
- Cipla Ltd.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson Services Inc.
- Medisol Lifescience Pvt. Ltd.
- Merck & Co., Inc.
- Mylan NV
- Novartis International AG
- Pfizer Inc.
- Sanofi SA
- Sumitomo Dainippon Pharma Co. Ltd.
- Teicos Pharma Ltd.
- Teva Pharmaceutical Industries Ltd.
- TFF Pharmaceuticals, Inc.
- Vectura Group Plc
- Verona Pharma plc
- Zambon S.p.A.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global inhalable drugs market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/inhalable-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
